Full Press Release Details
New Phase 3 Data Reinforce Long-Lasting Protection from Bleeding for Patients with Hemophilia A and B.
BIIB
New Phase 3 Data Reinforce Long-Lasting Protection from Bleeding for Patients with Hemophilia A and B
Key Takeaway: New Phase 3 Data Reinforce Long-Lasting Protection from Bleeding for Patients with Hemophilia A and B
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+34%
120-day peak, hindsight
Typical move
1.8%
average across 15 past catalysts
Lead asset
Alefacept
Phase 3 · Chronic Plaque Psoriasis